# Tusamitamab ravtansine

Source: https://onco.cc/drugs/tusamitamab-ravtansine/  
OnCo record `tusamitamab-ravtansine` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tusamitamab ravtansine was Sanofi's ADC against the classic CEA tumour marker, stopped for futility in lung cancer in 2023.

## Summary

A CEACAM5-directed ADC with a DM4 maytansinoid payload. Phase 3 CARMEN-LC03 (vs docetaxel in CEACAM5-high non-squamous NSCLC) was stopped in December 2023 when an interim analysis showed the PFS endpoint would not be met; OS was not improved. Sanofi discontinued the whole programme.

Lesson: a tubulin-inhibitor payload at DAR ~4 with a non-permeable release mechanism could not match the TOP1-payload ADC bar set in lung cancer; CEACAM5 itself remains under study with T-cell engagers.

## Fields

- Kind: Treatment
- Status: withdrawn
- Last checked: 2026-09-06
- Tags: failure; lesson:wrong-drug
- Code: SAR408701
- Modality: ADC
- Mechanism: Humanised anti-CEACAM5 IgG1 with DM4 via cleavable SPDB linker.
- Payload: DM4 (ravtansine)
- Linker: SPDB disulfide

## Sources

- Sanofi press release, CARMEN-LC03 (Dec 2023) (page moved; nearest live section): https://www.sanofi.com/en/media-room/press-releases/2023/

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [CEACAM5](https://onco.cc/targets/ceacam5/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)
- trials: [SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients](https://onco.cc/trials/nct04154956/), [Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC](https://onco.cc/trials/nct04524689/), [Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors](https://onco.cc/trials/nct04659603/)
- bottlenecks: [Failures are hidden](https://onco.cc/bottlenecks/b-negative-results/)
- biomarkers: [CEACAM5 expression](https://onco.cc/biomarkers/ceacam5-expression/)

---
JSON: https://onco.cc/api/v1/entities/tusamitamab-ravtansine.json